Company profile

Avalo Therapeutics, Inc.

Pipeline1 asset

AbdakibartAVTX-009 / IL-1β / Humanized IgG4 monoclonal antibody / Immune-mediated inflammatory diseases
Hidradenitis suppurativaPhase 2 completed; registrational Phase 3 plannedPositive topline Phase 2 LOTUS results reported May 5, 2026

Latest news10 items

May 22, 2026

Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

May 13, 2026

Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

Trial Results • Phase 2Topline results Tue, May 5, 2026

May 5, 2026

Avalo Therapeutics Announces Pricing of $375 Million Public Offering

May 5, 2026

Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

May 5, 2026

Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa

Trial Results • Phase 2

Apr 28, 2026

Avalo Therapeutics Purchases Optional Milestone Buyout

Mar 23, 2026

Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates

Feb 24, 2026

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Feb 18, 2026

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Feb 4, 2026

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Avalo Therapeutics, Inc. • Endpoint Arena